Journal of Clinical Oncology
Articles in this Issue
Apalutamide in patients with metastatic hormone-sensitive prostate cancer: Real-world experience and a retrospective multicenter analysis.
e17088 Background: The combination of androgen deprivation therapy (ADT) and apalutamide has improved survival outcomes for patients with metastatic hormo...
Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC).
1048 Background: Predictive biomarkers are needed to guide use of T-DXd, T-DM1 and SG in MBC. We used real-world comprehensive genomic profiling (CGP) of...
Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14–skipping+ NSCLC.
e20671 Background: First-line capmatinib (cap) and tepotinib (tep) have improved outcomes for patients with advanced MET Exon 14 Skipping+ NSCLC (METex14+...
Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data.
7066 Background: Three CAR-T cell therapies i.e. axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel are currently approved for relapse...
Spatial transcriptomics and functional mapping of the suppressive TME in primary breast tumor and breast-to-liver metastases.
e13119 Background: The tumor microenvironment (TME) of primary breast tumors (PTs) and breast-to-liver metastases shows heterogeneous infiltration and int...
Beyond the 5-year mark: Adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients.
523 Background: Extending adjuvant endocrine therapy (AET) beyond five years has been shown to be beneficial for women with non-metastatic, hormone-respon...
The PRO-CTCAE in oncology clinical trials: Insights from a targeted literature review.
e23193 Background: The Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a tool used to collect information on sympt...
Clinicopathological features and outcomes of patients with gastrointestinal stromal tumor at Instituto Nacional de Enfermedades Neoplásicas - Peru.
e23523 Background: Gastrointestinal Stromal Tumors (GIST) constitute 1-2% of primary gastrointestinal cancers. The incidence is less common in the Hispani...
Neoadjuvant immunotherapy and surgery in patients with stage IIIB-IIIC (N3) non-small cell lung cancer.
8045 Background: Stage IIIB-IIIC (N3) non-small cell lung cancer (NSCLC) is generally seen as unresectable, and Durvalumab following concurrent chemoradio...
State-level trends and associated disparities in melanoma burden in the United States.
1619 Background: Melanoma, an aggressive skin cancer, poses a significant public health challenge in the United States des...
Performance of previously described polygenic risk scores for prostate cancer in a population with mixed ancestry.
10578 Background: It is unclear whether polygenic risk scores (PRS) for prostate cancer (PrCa), developed using data from European populations, are applic...
Association of intestinal exfoliome and Prevotellaceae with toxicity and clinical outcome during immune-checkpoint blockade.
2664 Background: Immune-related adverse events (irAEs) are autoimmune side effects related to ICI, varying in severity, onset and organ involvement that m...
Association of Medicaid expansion with five-year survival after cancer diagnosis.
11006 Background: Medicaid expansion is associated with improvements in early detection, access to treatment, and increased 2-year cancer survival. Howeve...
Impact of liver cirrhosis on demographics and outcomes following esophagogastroduodenoscopy for non-variceal upper gastrointestinal bleeding in patients with gastric cancer.
e16055 Background: Non-variceal upper gastrointestinal bleeding (NVUGIB) is a common complication among gastric cancer patients. Esophagogastroduodenoscop...
Inferring FGFR status from H&E images using digital pathology to identify patients for early-stage bladder cancer targeted therapies.
4593 Background: The identification of susceptible FGFR (Fibroblast Growth Factor Receptor) alterations may be critical in guiding treatment decisions for...
Trends and disparities patterns in CAR-T therapy utilization, inpatient mortality, and adverse events in the United States (2017–2021).
e19500 Background: Since the FDA approved CAR-T therapy in August 2017, its utilization has steadily increased. However, limited data exist on variations...
Clinical, molecular characteristics, and outcomes of early-onset vs. late-onset colon cancer: A single-center experience.
e15692 Background: The incidence of colon cancer is increasing in those under 50 years of age(Early Onset Colon cancer {EOCC}). We evaluated clinical, mol...
Outpatient palliative care consultation and end-of-life outcomes among a retrospective cohort of patients treated with immunotherapy for non-small cell lung cancer.
12082 Background: Immune checkpoint inhibitors (ICIs) have been shown to be effective against a wide range of cancers and are available to most patients d...
A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).
e20004 Background: Early-stage non-small cell lung cancer (NSCLC) is known to have a different tumor microenvironment compared with advanced disease, whic...
Prostate cancer mortality trends in the US (1999–2020).
e23055 Background: Prostate cancer remains a leading cause of cancer-related mortality among U.S. men. This study evaluates mortality trends from 1999 to...
Real-world evidence from FLEX: Utility of MammaPrint in guiding treatment planning for patients aged 70 and older with early-stage breast cancer.
11175 Background: Older women (≥70) are less likely to receive chemotherapy (CT) due to quality-of-life concerns. Additionally, older patients are underre...
Oncology primary care clinics for comprehensive care of high-risk adolescent and young adult (AYA) cancer survivors.
1641 Background: Adolescent and young adult (AYA) cancer survivors experience early development of chronic medical conditions compared to healthy peers. D...
Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial.
4605 Background: HER2 expression is associated with poor efficacy of Bacillus Calmette-Guérin (BCG) instillation in patients (pts) with high-risk non-musc...
Impact of PDE5 inhibitor use on survival outcomes in male-predominant cancers: A propensity score-matched analysis.
e23325 Background: Phosphodiesterase-5 (PDE5) inhibitors, commonly prescribed for erectile dysfunction, exhibit immunomodulatory properties that may affec...
Safety and efficacy of eniluracil + capecitabine (6422 + Cap) in phase 1b trial.
e15152 Background: In comparison to the prior studies with eniluracil (6422) and 5-FU, 6422 + Cap uses a novel schedule of a single dose of 6422 followed...